The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008 of these patients underwent FFR guided revascularization and the rest QFR guided revascularization.
Primary end point was a composite of death, MI or unplanned revascularization at 12 months.
Both groups had well balanced baseline characteristics.
At 12-month follow-up, primary end point resulted 6.7% for QFR and 4.2% for FFR (HR 1.63; CI 95%: 1.11-2.41), with 2.5% difference (bilateral CI at 90%: 0.9%-4.2%), without reaching non-inferiority criteria.
The authors concluded the use of QFR is not recommended should FFR be available.
Presented by Birgitte Krogsgaard Andersen at TCT 2024.
